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cord blood units) in heavily pretreated pediatric patients with
hematologic malignancies, without the inclusion of ATG. Its efﬁ-
cacy in AML deserves further evaluation.
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MULTIPOTENT ADULT STEM CELLS
Verfaillie, C.M., Jiang, Y., Luttun, A., Ross, J., Oki, M., Seraﬁni, M.,
Buckley, S., Laksmipathy, U., Zeng, L., Tolar, J., Blazar, B. Stem Cell
Institute, University of Minnesota
The quintessential stem cell is the embryonal stem (ES) cell
which has unlimited self-renewal and multipotent differentiation
potential. Stem cells have also been identiﬁed in most tissues.
Compared with ES cells, tissue speciﬁc stem cells have less self-
renewal ability and, although they differentiate into multiple lin-
eages, they are not multipotent. A large number of recent pub-
lished studies have suggested that tissue speciﬁc stem cells may
have the ability to generate cells of tissues from unrelated organs.
We have identiﬁed a population of primitive cells in normal hu-
man, rodent, and swine post-natal tissues that have, at the single
cell level, multipotent differentiation and extensive proliferation
potential, which we named Multipotent Adult Progenitor Cell or
MAPC. Improved isolation processes have now generated cells
with Oct4 levels that vastly exceed the levels in MAPCs previously
published. This improvement has lead to signiﬁcantly greater dif-
ferentiation ability and signiﬁcantly greater in vivo engraftment
ability.
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WHARTON’S JELLY STEM CELLS: ISOLATION, EXTRACTION AND PRE-
LIMINARY CHARACTERIZATION
Cetrulo, C. Tufts University School of Medicine, Boston, MA
At the 2nd Annual International Cord Blood Symposium held in
May 2004, John Wagner stated that one of the goals for the
transplant community was to improve engraftment through three
novel approaches. Double unit transplantation, ex vivo expansion,
and a co-infusion of mesenchymal stem cells with hematopoietic
stem cells harvested from the cord blood. The combination of
umbilical cord matrix cells and the hematopoietic cord blood stem
cells fulﬁll these three requirements and may possibly lead to
quicker engraftment times for patients receiving cord blood trans-
plantation. Everyone is or should be interested in the placenta
because of the sources of stem cells that it provides. Stem cells can
be found in the placenta, amniotic ﬂuid, umbilical vein, decidua,
cord blood and also the Wharton’s Jelly (Umbilical Cord Matrix,
UCM). Characteristics of UCM stem cells include: Matrix Recep-
tors CD44, CD105, Integrin Markers CD29, CD51, MSC Mark-
ers SH2, SH3, and do not express CD34 and CD45. UCMs do not
express the Costimulatory, B7-1, B7-2 or CD40 or CD401. UCMs
are found to be negative for Class I MHC-/MHC-Class II in 95%
of the population following passage and cryopreservation. These
cells also express Oct-4. Wharton’s Jelly contains stem cells that
are a rich source of primitive multipotent mesenchymal cells with
high telomerase activity responsible for their self-renewal capacity
and immortality and have the capability to differentiate into bone,
cartilage, muscle cells (cardiac) and nerve cells. The goal is to
develop these cells as accessory supporting cells for cord blood
transplantation.
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INTERNATIONAL STANDARDS AND ACCREDITATION IN CORD BLOOD
BANKING AND CELLULAR THERAPY: THE FOUNDATION FOR THE AC-
CEDITATION OF CELLULAR THERAPY
Warkentin, P.I. University of Nebraska Medical Center, Omaha, NE
The Foundation for the Accreditation of Cellular Therapy
(FACT) was founded in 1996 by the American Society for Blood
and Marrow Transplant and the International Society for Cellular
Therapy to establish standards and a voluntary inspection and
accreditation program for quality patient medical care and labora-
tory practice in hematopoietic cellular therapy, while preserving
the essential research environment. Two hundred twenty nine
hematopoietic cell transplant programs have applied for accredita-
tion; and currently one hundred thirty two have achieved accred-
itation. FACT collaborated to develop international standards for
cord blood banking with NETCORD, a foundation of member
cord blood banks established to globally unite the supply and
demand of umbilical cord blood and to maintain world-wide stan-
dards and a system of quality approval in the area of umbilical cord
blood. The goals of NETCORD-FACT International Standards
for Cord Blood Collection, Processing, Testing, Banking, Selec-
tion and Release are to promote quality practices and to consis-
tently assure provision of quality cord blood units for transplanta-
tion. NETCORD-FACT Standards encompass all phases of cord
blood for transplantation. A Cord Blood Bank is deﬁned as an
integrated team responsible for the collection, processing, testing,
banking, selection and release of CB units for transplantation. No
speciﬁc bank structure is required, however, there must be a pro-
cess to meet all of the standards. Standards require all cord blood
banks to maintain a comprehensive Quality Management Program
overseen by a designated individual; to utilize validated methods,
supplies, reagents, and equipment; to document personnel qualiﬁ-
cation, training and continued competence; and to maintain the
details of clinical outcome, including at least viability and cell yield
of the CB unit, adverse events during infusion, and recipient
engraftment, survival, graft versus host disease and chimerism.
These Standards do not encompass the clinical use of cord blood
units, which is covered in the FACT clinical standards for trans-
plant programs. FACT-NETCORD accreditation is voluntary,
open to both public and private banks, and intended to be educa-
tional and collegial, to raise the standard of quality in all banks.
Currently, thirty-nine Cord Blood Banks from the United States,
United Kingdom, Europe and Asia have applied for FACT-NET-
CORD accreditation. Of these, 11 have completed the on-site
inspection and seven are fully accredited.
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AABB STANDARDS AND ACCREDITATION FOR CORD BLOOD
Loper, K.1, Otter, J.1, Rapp, H.1, McMannis, J. (presenter)2. 1. AABB,
Bethesda, MD; 2. M.D. Anderson Medical Center, Houston, TX
For almost 60 years, the AABB (formerly American Association
of Blood Banks) has been the preeminent leader in transfusion
medicine with 8,000 individual members and 1,800 institutional
members. AABB had applied its extensive experience in standard
setting, education and accreditation programs to related biological
therapies including cord blood collection and processing. AABB is
dedicated to ensuring that patients who provide or are treated with
cord blood receive the best care, with a strong focus on the
laboratory processes and the cord blood product itself including
post-transplant outcomes. In 2004 AABB incorporated its cord
blood standards into the Standards for Cellular Therapy Services.
These standards integrate quality management systems with tech-
nical requirements. These standards apply to donor selection, eli-
gibility, product processing, storage and issuance, including out-
comes data collection. Standards are revised every 2 years but
interim or emergent standards can be issued at any time as circum-
stances warrant. AABB’s accreditation program is systems based
and assesses compliance to requirements in the Standards via the
collection of objective evidence. Non-conformances must be
linked to a speciﬁc standard and when identiﬁed, require the
formulation and implementation of a corrective action plan. The
assessment team is composed of a lead assessor and team members
with 5 years experience in HPC and cord blood activities. As-
sessors undergo initial training and are required to maintain spe-
ciﬁc levels of continuing education in designated subjects. Cur-
rently, there are 22 AABB accredited cord blood banks, both public
and private, national and international. Due to the signiﬁcant
improvements in the new standards, AABB began reassessing cord
blood facilities against the new standards May 1, 2005. AABB
commends Congress and the IOM for commissioning the Institute
of Medicine Cord Blood Study Committee and its recommenda-
tion for a national, federally funded program. AABB supports
consistency in standard setting and continues to work with orga-
nizations to establish uniform cord blood standards for all cord
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blood recipients. AABB works closely with other organizations
including FDA, ISCT, NMDP, FACT and ASBMT sponsoring
joint educational programs and serving on joint committees. How-
ever, AABB believes each organization brings speciﬁc experience
and expertise to a national cord blood program.
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INSTITUTE OF MEDICINE REPORT ON CORD BLOOD TRANSPLANTA-
TION
Champlin, R. M.D. Anderson Cancer Center, Houston, TX
In 2004 Congress appropriated $10 million for the establishment
of a National Stem Cell Bank Program under the Health Re-
sources and Services Administration. The Institute of Medicine
was commissioned to review the use of cord blood for stem cell
treatment and make recommendations regarding a national system
to support cord blood transplantation. The committee noted the
success and value of cord blood as a source of stem cells for
transplantation. The committee recommended that a National
Cord Blood Policy Board be established to set policy and advise the
Department of Health and Human Safety on policy regarding
donation collections and uses of cord blood, as well as research
needed to advance the ﬁeld. The committee recommended that the
structure of the national program include a cord blood accredita-
tion organization a coordinating center encompassing search ac-
tivities and outcomes analysis. The report recommended establish-
ment of uniform standards for cord blood collection, and a quality
assurance system. The committee recommended that FDA license
cord blood banks. The committee recognized the discussed ethical
and legal issues involved with donor consent, conﬁdentiality and
banking. The committee recognized that funding is needed to
build inventory and recommended that a national inventory of
100,000 new high quality units is needed, and a national inventory
policy be developed. Outcomes research regarding cord blood
transplants is needed; fundamental to this process is a national
database collecting comprehensive data on all cord blood trans-
plants, as well as other stem cell sources.
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